Collegium Pharmaceutical, Inc. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
Collegium Pharmaceutical, Inc. (COLL) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $110.54 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-08-06
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $110.54M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $138.73M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $55.47M.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $110.94M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $110.54M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $138.73M 10-Q · filed 2026-05-07 |
| 2025-09-30 | $55.47M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $110.94M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $166.42M 10-Q · filed 2025-05-08 |
| 2024-09-30 | $55.47M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $69.03M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $103.55M 10-Q · filed 2024-05-09 |
| 2023-09-30 | $34.51M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $74.93M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $112.39M 10-Q · filed 2023-05-04 |
| 2022-09-30 | $37.55M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $75.10M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $114.23M 10-Q · filed 2022-05-10 |
| 2021-09-30 | $16.80M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $33.59M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $50.39M 10-Q · filed 2021-05-06 |
| 2020-09-30 | $16.80M 10-Q · filed 2020-11-05 |
| 2018-09-30 | $32.41M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $64.81M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $97.22M 10-Q · filed 2018-05-09 |
| 2017-09-30 | $47.00K 10-Q · filed 2017-11-08 |
| 2017-06-30 | $95.00K 10-Q · filed 2017-08-09 |
| 2017-03-31 | $143.00K 10-Q · filed 2017-05-10 |
| 2016-09-30 | $170.00K 10-Q · filed 2016-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |